Ipilimumab/nivolumabVarious immune related adverse events: 15 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1762卷 / 1期

关键词：

D O I：

10.1007/s40278-019-64959-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：220 / 220

相关论文

共 50 条

[31] Ipilimumab/nivolumabVarious toxicities: 2 case reports
Reactions Weekly, 2020, 1790 (1) : 141 - 141
[32] Ipilimumab/nivolumabVarious toxicities: 2 case reports
Reactions Weekly, 2017, 1676 (1) : 175 - 175
[33] Ipilimumab/nivolumabVarious toxicities: 6 case reports
Reactions Weekly, 2020, 1835 (1) : 228 - 228
[34] Ipilimumab/nivolumabVarious toxicities: 3 case reports
Reactions Weekly, 2022, 1902 (1) : 255 - 255
[35] Ipilimumab/nivolumabVarious toxicities: 3 case reports
Reactions Weekly, 2021, 1865 (1) : 242 - 242
[36] Ipilimumab/nivolumabVarious toxicities: 5 case reports
Reactions Weekly, 2019, 1737 (1) : 172 - 172
[37] Ipilimumab/nivolumabVarious toxicities: 18 case reports
Reactions Weekly, 2018, 1705 (1) : 175 - 175
[38] Ipilimumab/nivolumabVarious toxicities: 2 case reports
Reactions Weekly, 2018, 1693 (1) : 278 - 278
[39] Ipilimumab/nivolumab/pembrolizumabImmune-related adverse events: 33 case reports
Reactions Weekly, 2018, 1692 (1) : 191 - 191
[40] Ipilimumab/Nivolumab/PembrolizumabImmune-related adverse events: 13 case reports
Reactions Weekly, 2024, 2028 (1) : 255 - 255

← 1 2 3 4 5 →